Middle East Pharmaceutical Industries Past Earnings Performance
Past criteria checks 6/6
Middle East Pharmaceutical Industries has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 11.5% per year. Middle East Pharmaceutical Industries's return on equity is 24.7%, and it has net margins of 20.8%.
Key information
2.7%
Earnings growth rate
2.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 11.5% |
| Return on equity | 24.7% |
| Net Margin | 20.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Middle East Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 387 | 80 | 153 | 0 |
| 30 Jun 24 | 367 | 79 | 141 | 0 |
| 31 Mar 24 | 359 | 76 | 133 | 0 |
| 31 Dec 23 | 338 | 66 | 129 | 0 |
| 30 Sep 23 | 294 | 41 | 120 | 0 |
| 30 Jun 23 | 318 | 59 | 122 | 0 |
| 31 Mar 23 | 291 | 50 | 117 | 0 |
| 31 Dec 22 | 303 | 59 | 114 | 0 |
| 31 Dec 21 | 287 | 66 | 98 | 0 |
| 31 Dec 20 | 302 | 73 | 95 | 0 |
Quality Earnings: 4016 has high quality earnings.
Growing Profit Margin: 4016's current net profit margins (20.8%) are higher than last year (14%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4016's earnings have grown by 2.7% per year over the past 5 years.
Accelerating Growth: 4016's earnings growth over the past year (94.7%) exceeds its 5-year average (2.7% per year).
Earnings vs Industry: 4016 earnings growth over the past year (94.7%) exceeded the Pharmaceuticals industry 7.5%.
Return on Equity
High ROE: 4016's Return on Equity (24.7%) is considered high.